ADL outcome · people with stroke
The review found no eligible studies for this question.
2 findings from 1 review
Secondary outcome measure: mean upper extremity function at the end of the intervention periodClinical measures of upper extremity function. Scale from: 0 to infinity. · people with stroke
2 findings from 1 review
Secondary outcome measure: hemispatial neglect at the end of · people with stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome measure: lower extremity function at the end of · people with stroke
1 finding from 1 review
Muscle strength · people with stroke
1 finding from 1 review
Secondary outcome measure: cognitive abilities at the end of · people with stroke
1 finding from 1 review
Secondary outcome measure: hemispatial neglect at the end of · people with stroke
1 finding from 1 review
Dropouts, adverse events and deaths during intervention phase Numbers of dropouts, adverse events and deaths from all causes · people with stroke
tDCS showed no clear difference in secondary outcome measure: dropouts, adverse events and deaths… compared with any type of placebo or passive control intervention (moderate certainty).
1 finding from 1 review
Outcomes at ≥ 3 months · preventing early recurrence after ischaemic stroke or TIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · preventing early recurrence after ischaemic stroke or TIA
Dual probably leads to lower stroke compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in vascular death compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Myocardial infarction · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in myocardial infarction compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Stroke, myocardial infarction, or vascular death · preventing early recurrence after ischaemic stroke or TIA
Dual probably leads to lower stroke, myocardial infarction, or vascular death compared with one antiplatelet agent (moderate certainty).
1 finding from 1 review
Intracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Dual showed no clear difference in intracranial haemorrhage compared with one antiplatelet agent (low certainty).
1 finding from 1 review
Extracranial haemorrhage · preventing early recurrence after ischaemic stroke or TIA
Dual leads to higher extracranial haemorrhage compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Ischaemic stroke · preventing early recurrence after ischaemic stroke or TIA
Dual leads to lower ischaemic stroke compared with one antiplatelet agent (high certainty).
1 finding from 1 review
Stroke · preventing early recurrence after ischaemic stroke or TIA
Multiple probably leads to lower stroke compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review
Deaths due to vascular events · preventing early recurrence after ischaemic stroke or TIA
Multiple showed no clear difference in vascular death compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review
Myocardial infarction · preventing early recurrence after ischaemic stroke or TIA
Multiple showed no clear difference in myocardial infarction compared with fewer antiplatelet agents (high certainty).
1 finding from 1 review
Stroke, myocardial infarction, or vascular death · preventing early recurrence after ischaemic stroke or TIA
Multiple probably leads to lower stroke, myocardial infarction, or vascular death compared with fewer antiplatelet agents (moderate certainty).
1 finding from 1 review